Zenyatta Ventures Ltd Stock Toronto S.E.
Equities
CA98943A1012
Biotechnology & Medical Research
Sales 2022 | 0.35 0.48 | Sales 2023 | 0.07 0.1 | Capitalization | 206M 282M |
---|---|---|---|---|---|
Net income 2022 | -38M -52.01M | Net income 2023 | -14M -19.16M | EV / Sales 2022 | 1,031,593,065 x |
Net cash position 2022 | 24.44M 33.45M | Net cash position 2023 | 8.75M 11.97M | EV / Sales 2023 | 2,707,984,696 x |
P/E ratio 2022 |
-9.19
x | P/E ratio 2023 |
-14.3
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 94.07% |
Managers | Title | Age | Since |
---|---|---|---|
Gregory Fenton
CEO | Chief Executive Officer | - | 18-07-10 |
Wendy Ford
DFI | Director of Finance/CFO | - | 22-05-15 |
Adam MacIntosh
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Ilse Treurnicht
BRD | Director/Board Member | - | 22-07-04 |
John Snisarenko
BRD | Director/Board Member | 61 | 23-10-04 |
Francis Dubé
COO | Chief Operating Officer | - | 18-05-10 |
1st Jan change | Capi. | |
---|---|---|
+4.09% | 43.84B | |
+47.81% | 41.25B | |
+9.45% | 41.68B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+29.70% | 12.29B | |
+1.28% | 12.29B | |
+7.78% | 11.15B |